Avraham Hava Karsenty, Jiang Shuxian, Lee Tae-Hee, Prakash Om, Avraham Shalom
Division of Experimental Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 4 Blackfan Circle, Boston, MA 02115, USA.
J Immunol. 2004 Nov 15;173(10):6228-33. doi: 10.4049/jimmunol.173.10.6228.
The blood-brain barrier (BBB) is a network formed mainly by brain microvascular endothelial cells (BMECs). The integrity of the BBB is critical for brain function. Breakdown of the BBB is commonly seen in AIDS patients with HIV-1-associated dementia despite the lack of productive HIV infection of the brain endothelium. The processes by which HIV causes these pathological conditions are not well understood. In this study we characterized the molecular mechanisms by which Tat mediates its pathogenic effects in vitro on primary human BMECs (HBMECs). Tat treatment of HBMECs stimulated cytoskeletal organization and increased focal adhesion sites compared with control cells or cells treated with heat-inactivated Tat. Pretreatment with Tat Abs or with the specific inhibitor SU-1498, which interferes with vascular endothelial growth factor receptor type 2 (Flk-1/KDR) phosphorylation, blocked the ability of Tat to stimulate focal adhesion assembly and the migration of HBMECs. Focal adhesion kinase (FAK) was tyrosine-phosphorylated by Tat and was found to be an important component of focal adhesion sites. Inhibition of FAK by the dominant interfering mutant form, FAK-related nonkinase, significantly blocked HBMEC migration and disrupted focal adhesions upon Tat activation. Furthermore, HIV-Tat induced permeability changes in HBMECs in a time-dependent manner. Tat also impaired BBB permeability, as observed in HIV-1 Tat transgenic mice. These studies define a mechanism for HIV-1 Tat in focal adhesion complex assembly in HBMECs via activation of FAK, leading to cytoskeletal reorganization and permeability changes.
血脑屏障(BBB)主要由脑微血管内皮细胞(BMECs)形成的网络组成。血脑屏障的完整性对脑功能至关重要。尽管脑内皮细胞缺乏有效的HIV感染,但在患有HIV-1相关痴呆的艾滋病患者中,血脑屏障的破坏很常见。HIV导致这些病理状况的过程尚不清楚。在本研究中,我们描述了Tat在体外对原代人BMECs(HBMECs)介导其致病作用的分子机制。与对照细胞或用热灭活Tat处理的细胞相比,用Tat处理HBMECs可刺激细胞骨架组织并增加粘着斑位点。用Tat抗体或特异性抑制剂SU-1498预处理,后者可干扰血管内皮生长因子受体2型(Flk-1/KDR)磷酸化,可阻断Tat刺激粘着斑组装和HBMECs迁移的能力。粘着斑激酶(FAK)被Tat酪氨酸磷酸化,并且被发现是粘着斑位点的重要组成部分。通过显性干扰突变体形式FAK相关非激酶抑制FAK,可显著阻断Tat激活后HBMECs的迁移并破坏粘着斑。此外,HIV-Tat以时间依赖性方式诱导HBMECs的通透性变化。如在HIV-1 Tat转基因小鼠中观察到的,Tat也损害了血脑屏障的通透性。这些研究确定了HIV-1 Tat通过激活FAK在HBMECs粘着斑复合物组装中的机制,导致细胞骨架重组和通透性变化。